FDA Approves Drug Product Manufacturing for Samsung BioLogics
Drug product approval from FDA follows previous approvals from European and Japanese authorities.
Samsung BioLogics announced on July 25, 2018 that it has been licensed by FDA to manufacture a monoclonal antibody drug product at its Songdo Plant 1. The company has 16 global approvals for manufacturing drug substance in Plant 1 and 2, and drug products in Plant 1 including two European Medicines Agency drug product approvals and one Pharmaceuticals and Medical Device Agency (Japan) drug product approval.
In a statement announcing the FDA approval, Samsung BioLogics reported the company expects additional global drug substance and drug product approvals for both Plant 1 and Plant 2 during the second half of 2018.
Source: Samsung Biologics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
